Participation of cytoskeleton on the cardiac muscarinic cholinergic effects of anti-laminin IgG.

BACMAN, S.; STERIN-BORDA, L.; LUSTIG, L.; DENDUCHIS, B.; BORDA, E.

BRITISH JOURNAL OF PHARMACOLOGY

WILEY-BLACKWELL PUBLISHING, INC

Año: 1994 vol. 111 p. 271 - 277

0007-1188

1. We have previously demonstrated a molecular relationship between laminin and cardiac cholinoceptors. 2. We have now explored the participation of cytoskeletal proteins in the interaction between an antilaminin IgG with cardiac cholinoceptors. 3. Antilaminin IgG, whilst it specifically reacts with laminin molecules was able to induce cardiac cholinoceptor activation; acting like an agonist, decreasing cyclic AMP concentrations, reducing heart contractility and increasing phosphoinositide turnover. 4. Antilaminin IgG also interfered with the binding of a radiolabelled muscarinic antagonist, [3H]-quinuclidinyl benzilate. Colchicine and cytochalasin B, drugs that are able to prevent microfilament and microtubule polimerization, impaired the binding of antilaminin IgG to muscarinic cholinoceptors. 5. Cytochalasin B but not colchicine modified the muscarinic cholinoceptor effects mediated by regulatory G proteins (cyclic AMP and contractility) induced by antilaminin IgG. 6. It was demonstrated, by immunofluorescence, that none of these disrupting drugs altered the specific recognition of the antibody by its antigen. 7. These data indirectly suggest the participation of the cytoskeleton in the laminin and cholinergic receptor association.